This limitation prevents us from addressing questions such as the effectiveness or cost-effectiveness of interventions to prevent admission for UGH. Although we analyzed pre-admission PPI or COX-2 use in at-risk patients as preventive therapy, we are unable to determine the actual intent of the physician in prescribing these drugs.